Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response

por Rexer, Brent N, Arteaga, Carlos L
Publicado 2014

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

por Miller, Todd W, Rexer, Brent N, Garrett, Joan T, Arteaga, Carlos L
Publicado 2011

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

por Rexer, Brent N, Chanthaphaychith, Siprachanh, Dahlman, Kimberly Brown, Arteaga, Carlos L
Publicado 2014

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3

por Chakrabarty, Anindita, Rexer, Brent N., Wang, Shizhen Emily, Cook, Rebecca S., Engelman, Jeffrey A., Arteaga, Carlos, L.
Publicado 2010

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

por Rexer, Brent N., Ham, Amy-Joan L., Rinehart, Cammie, Hill, Salisha, Granja-Ingram, Nara de Matos, González, Ana María, Mills, Gordon B., Dave, Bhuvanesh, Chang, Jenny C., Liebler, Daniel C., Arteaga, Carlos L.
Publicado 2011

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

por Tolaney, Sara M., Beeram, Muralidhar, Beck, J. Thaddeus, Conlin, Alison, Dees, E. Claire, Puhalla, Shannon L., Rexer, Brent N., Burris, Howard A., Jhaveri, Komal, Helsten, Teresa, Becerra, Carlos, Kalinsky, Kevin, Moore, Kathleen N., Manuel, Allison M., Lithio, Andrew, Price, Gregory L., Chapman, Sonya C., Litchfield, Lacey M., Goetz, Matthew P.
Publicado 2022